106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2019 All rights reserved
ASCORIS1973
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to suggest
any particular course of medical treatment. Use of the practice guidelines and this resource are
voluntary. e practice guidelines and additional information are available at www.asco.org/breast-
cancer-guidelines. Copyright © 2019 by American Society of Clinical Oncolog y. All rights reserved.
Source
Kala Visvanathan, Patricia Hurley, Elissa Bantug, Powel Brown, Nananda F. Col, Jack Cuzick,
Nancy E. Davidson, Andrea DeCensi, Carol Fabian, Leslie Ford, Judy Garber, Maria Katapodi,
Barnett Kramer, Monica Morrow, Barbara Parker, Carolyn Runowicz, Victor G. Vogel III, James
L. Wade, and Scott M. Lippman. Use of pharmacologic interventions for breast cancer risk
reduction: American Society of Clinical Oncolog y clinical practice guideline. J Clin Oncol.
2013 Aug 10;31(23):2942-62.
Kala Visvanathan, Carol J. Fabian, Elissa Bantug, Abenaa M. Brewster, Nancy E. Davidson,
Andrea DeCensi, Justin D. Floyd, Judy E. Garber, Erin W. Hofstatter, Seema A. Khan, Maria C.
Katapodi, Sandhya Pruthi, Rachal Raab, Carolyn D. Runowicz, and Mark R. Somerfield. Use
of Endocrine erapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline
Update
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical tools
and resources, is available at www.asco.org/breast-cancer-guidelines.
Abbreviations
ASCO, American Society of Clinical Oncolog y; BC, breast cancer; d, day; DCIS, ductal
carcinoma in situ; ER, estrogen receptor; FDA, US Food and Drug Administration; LCIS,
lobular carcinoma in situ; mg, milligram; NCI, National Cancer Institute; SERM, selective
estrogen receptor modulator
